APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neurodegenerative Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Neurodegenerative Drugs Industry Research Report 2026

19 December 2025137 pages

Choose your research edition.

Industry ResearchNeurodegenerative Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Neurodegenerative Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neurodegenerative Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neurodegenerative Drugs Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Neurodegenerative Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Neurodegenerative Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Neurodegenerative Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Neurodegenerative Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Neurodegenerative Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Neurodegenerative Drugs include TEVA, Sanofi, Novartis, Luye Pharma, Livzon Pharmaceutical, Kanghong Pharmaceutical, Jingxin Pharmaceutical, Pfizer and Huahai Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Neurodegenerative Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (Tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Tons) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Neurodegenerative Drugs Market by Company

TEVA

Sanofi

Novartis

Luye Pharma

Livzon Pharmaceutical

Kanghong Pharmaceutical

Jingxin Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hisun Pharmaceutical

Haisco Pharmaceutical

GlaxoSmithKline

Ark Pharmaceutical

Dongcheng Biochemicals

BORA PHARMACEUTICALS

UCB

Merck Serono

Boehringer Ingelheim

Biogen Idec

Neurodegenerative Drugs Segment by Type

NMDA

SSRIs

Dopamine Inhibitors

Neurodegenerative Drugs Segment by Application

Parkinson’s Disease

Amyotrophic Lateral Sclerosis

Huntington Disease

Alzheimer’s Disease

Neurodegenerative Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neurodegenerative Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neurodegenerative Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neurodegenerative Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Neurodegenerative Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neurodegenerative Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Neurodegenerative Drugs Sales (Tons) of Manufacturers (2021-2026) Table 7. Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Neurodegenerative Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Neurodegenerative Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Neurodegenerative Drugs Average Price (US$/Ton) of Manufacturers (2021-2026) Table 11. Global Neurodegenerative Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Neurodegenerative Drugs, Product Type & Application Table 14. Global Neurodegenerative Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Neurodegenerative Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. TEVA Company Information Table 19. TEVA Business Overview Table 20. TEVA Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 21. TEVA Neurodegenerative Drugs Product Portfolio Table 22. TEVA Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 26. Sanofi Neurodegenerative Drugs Product Portfolio Table 27. Sanofi Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 31. Novartis Neurodegenerative Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Luye Pharma Company Information Table 34. Luye Pharma Business Overview Table 35. Luye Pharma Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 36. Luye Pharma Neurodegenerative Drugs Product Portfolio Table 37. Luye Pharma Recent Developments Table 38. Livzon Pharmaceutical Company Information Table 39. Livzon Pharmaceutical Business Overview Table 40. Livzon Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 41. Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 42. Livzon Pharmaceutical Recent Developments Table 43. Kanghong Pharmaceutical Company Information Table 44. Kanghong Pharmaceutical Business Overview Table 45. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 46. Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 47. Kanghong Pharmaceutical Recent Developments Table 48. Jingxin Pharmaceutical Company Information Table 49. Jingxin Pharmaceutical Business Overview Table 50. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 51. Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 52. Jingxin Pharmaceutical Recent Developments Table 53. Pfizer Company Information Table 54. Pfizer Business Overview Table 55. Pfizer Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 56. Pfizer Neurodegenerative Drugs Product Portfolio Table 57. Pfizer Recent Developments Table 58. Huahai Pharmaceutical Company Information Table 59. Huahai Pharmaceutical Business Overview Table 60. Huahai Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 61. Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 62. Huahai Pharmaceutical Recent Developments Table 63. Hisun Pharmaceutical Company Information Table 64. Hisun Pharmaceutical Business Overview Table 65. Hisun Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 66. Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 67. Hisun Pharmaceutical Recent Developments Table 68. Haisco Pharmaceutical Company Information Table 69. Haisco Pharmaceutical Business Overview Table 70. Haisco Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 71. Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 72. Haisco Pharmaceutical Recent Developments Table 73. GlaxoSmithKline Company Information Table 74. GlaxoSmithKline Business Overview Table 75. GlaxoSmithKline Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Neurodegenerative Drugs Product Portfolio Table 77. GlaxoSmithKline Recent Developments Table 78. Ark Pharmaceutical Company Information Table 79. Ark Pharmaceutical Business Overview Table 80. Ark Pharmaceutical Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio Table 82. Ark Pharmaceutical Recent Developments Table 83. Dongcheng Biochemicals Company Information Table 84. Dongcheng Biochemicals Business Overview Table 85. Dongcheng Biochemicals Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio Table 87. Dongcheng Biochemicals Recent Developments Table 88. BORA PHARMACEUTICALS Company Information Table 89. BORA PHARMACEUTICALS Business Overview Table 90. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio Table 92. BORA PHARMACEUTICALS Recent Developments Table 93. UCB Company Information Table 94. UCB Business Overview Table 95. UCB Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. UCB Neurodegenerative Drugs Product Portfolio Table 97. UCB Recent Developments Table 98. Merck Serono Company Information Table 99. Merck Serono Business Overview Table 100. Merck Serono Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Merck Serono Neurodegenerative Drugs Product Portfolio Table 102. Merck Serono Recent Developments Table 103. Boehringer Ingelheim Company Information Table 104. Boehringer Ingelheim Business Overview Table 105. Boehringer Ingelheim Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio Table 107. Boehringer Ingelheim Recent Developments Table 108. Biogen Idec Company Information Table 109. Biogen Idec Business Overview Table 110. Biogen Idec Neurodegenerative Drugs Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 111. Biogen Idec Neurodegenerative Drugs Product Portfolio Table 112. Biogen Idec Recent Developments Table 113. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Neurodegenerative Drugs Sales by Region (2021-2026) & (Tons) Table 115. Global Neurodegenerative Drugs Sales Market Share by Region (2021-2026) Table 116. Global Neurodegenerative Drugs Sales by Region (2027-2032) & (Tons) Table 117. Global Neurodegenerative Drugs Sales Market Share by Region (2027-2032) Table 118. Global Neurodegenerative Drugs Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Neurodegenerative Drugs Revenue Market Share by Region (2021-2026) Table 120. Global Neurodegenerative Drugs Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Neurodegenerative Drugs Revenue Market Share by Region (2027-2032) Table 122. North America Neurodegenerative Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 124. North America Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 125. North America Neurodegenerative Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Neurodegenerative Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Neurodegenerative Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 129. Europe Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 130. Europe Neurodegenerative Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Neurodegenerative Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Neurodegenerative Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 134. Asia Pacific Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 135. Asia Pacific Neurodegenerative Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Neurodegenerative Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Neurodegenerative Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 139. South America Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 140. South America Neurodegenerative Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Neurodegenerative Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Neurodegenerative Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Neurodegenerative Drugs Sales by Country (2021-2026) & (Tons) Table 144. Middle East and Africa Neurodegenerative Drugs Sales by Country (2027-2032) & (Tons) Table 145. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Neurodegenerative Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Neurodegenerative Drugs Sales by Type (2021-2026) & (Tons) Table 148. Global Neurodegenerative Drugs Sales by Type (2027-2032) & (Tons) Table 149. Global Neurodegenerative Drugs Sales Market Share by Type (2021-2026) Table 150. Global Neurodegenerative Drugs Sales Market Share by Type (2027-2032) Table 151. Global Neurodegenerative Drugs Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Neurodegenerative Drugs Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2026) Table 154. Global Neurodegenerative Drugs Revenue Market Share by Type (2027-2032) Table 155. Global Neurodegenerative Drugs Price by Type (2021-2026) & (US$/Ton) Table 156. Global Neurodegenerative Drugs Price by Type (2027-2032) & (US$/Ton) Table 157. Global Neurodegenerative Drugs Sales by Application (2021-2026) & (Tons) Table 158. Global Neurodegenerative Drugs Sales by Application (2027-2032) & (Tons) Table 159. Global Neurodegenerative Drugs Sales Market Share by Application (2021-2026) Table 160. Global Neurodegenerative Drugs Sales Market Share by Application (2027-2032) Table 161. Global Neurodegenerative Drugs Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Neurodegenerative Drugs Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2026) Table 164. Global Neurodegenerative Drugs Revenue Market Share by Application (2027-2032) Table 165. Global Neurodegenerative Drugs Price by Application (2021-2026) & (US$/Ton) Table 166. Global Neurodegenerative Drugs Price by Application (2027-2032) & (US$/Ton) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Neurodegenerative Drugs Distributors List Table 170. Neurodegenerative Drugs Customers List Table 171. Neurodegenerative Drugs Industry Trends Table 172. Neurodegenerative Drugs Industry Drivers Table 173. Neurodegenerative Drugs Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Neurodegenerative Drugs Product Image Figure 5. Global Neurodegenerative Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Neurodegenerative Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Neurodegenerative Drugs Sales (2021-2032) & (Tons) Figure 8. Global Neurodegenerative Drugs Average Price (US$/Ton) & (2021-2032) Figure 9. NMDA Product Image Figure 10. SSRIs Product Image Figure 11. Dopamine Inhibitors Product Image Figure 12. Parkinson’s Disease Product Image Figure 13. Amyotrophic Lateral Sclerosis Product Image Figure 14. Huntington Disease Product Image Figure 15. Alzheimer’s Disease Product Image Figure 16. Global Neurodegenerative Drugs Revenue Share by Manufacturers in 2025 Figure 17. Global Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters Figure 18. Global Top 5 and 10 Neurodegenerative Drugs Players Market Share by Revenue in 2025 Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Neurodegenerative Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 21. Global Neurodegenerative Drugs Sales by Region in 2025 Figure 22. Global Neurodegenerative Drugs Revenue by Region in 2025 Figure 23. North America Neurodegenerative Drugs Market Size by Country in 2025 Figure 24. North America Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 25. North America Neurodegenerative Drugs Revenue Market Share by Country (2021-2032) Figure 26. United States Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Canada Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Neurodegenerative Drugs Market Size by Country in 2025 Figure 29. Europe Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 30. Europe Neurodegenerative Drugs Revenue Market Share by Country (2021-2032) Figure 31. Germany Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Netherlands Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Nordic Countries Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Neurodegenerative Drugs Market Size by Country in 2025 Figure 38. Asia Pacific Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Neurodegenerative Drugs Revenue Market Share by Country (2021-2032) Figure 40. China Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Neurodegenerative Drugs Market Size by Country in 2025 Figure 49. South America Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 50. South America Neurodegenerative Drugs Revenue Market Share by Country (2021-2032) Figure 51. Mexico Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Colombia Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Middle East and Africa Neurodegenerative Drugs Market Size by Country in 2025 Figure 56. Middle East and Africa Neurodegenerative Drugs Sales Market Share by Country (2021-2032) Figure 57. Middle East and Africa Neurodegenerative Drugs Revenue Market Share by Country (2021-2032) Figure 58. Turkey Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. UAE Neurodegenerative Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Global Neurodegenerative Drugs Sales Market Share by Type (2021-2032) Figure 62. Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2032) Figure 63. Global Neurodegenerative Drugs Price (US$/Ton) by Type (2021-2032) Figure 64. Global Neurodegenerative Drugs Sales Market Share by Application (2021-2032) Figure 65. Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2032) Figure 66. Global Neurodegenerative Drugs Price (US$/Ton) by Application (2021-2032) Figure 67. Neurodegenerative Drugs Value Chain Figure 68. Neurodegenerative Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Neurodegenerative Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • NMDA
  • SSRIs
  • Dopamine Inhibitors
Applications
  • Parkinson’s Disease
  • Amyotrophic Lateral Sclerosis
  • Huntington Disease
  • Alzheimer’s Disease
Companies covered
  • TEVA
  • Sanofi
  • Novartis
  • Luye Pharma
  • Livzon Pharmaceutical
  • Kanghong Pharmaceutical
  • Jingxin Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hisun Pharmaceutical
  • Haisco Pharmaceutical
  • GlaxoSmithKline
  • Ark Pharmaceutical
  • Dongcheng Biochemicals
  • BORA PHARMACEUTICALS
  • UCB
  • Merck Serono
  • Boehringer Ingelheim
  • Biogen Idec

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Neurodegenerative Drugs Market Size (2021-2032)
  4. 2.2.2 Global Neurodegenerative Drugs Sales (2021-2032)
  5. 2.2.3 Global Neurodegenerative Drugs Market Average Price (2021-2032)
  6. 2.3 Neurodegenerative Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 NMDA
  9. 2.3.3 SSRIs
  10. 2.3.4 Dopamine Inhibitors
  11. 2.4 Neurodegenerative Drugs by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Parkinson’s Disease
  14. 2.4.3 Amyotrophic Lateral Sclerosis
  15. 2.4.4 Huntington Disease
  16. 2.4.5 Alzheimer’s Disease
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Neurodegenerative Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Neurodegenerative Drugs Sales (Tons) of Manufacturers (2021-2026)
  3. 3.3 Global Neurodegenerative Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Neurodegenerative Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Neurodegenerative Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Neurodegenerative Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Neurodegenerative Drugs, Established Date
  9. 3.9 Global Neurodegenerative Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 TEVA
  2. 4.1.1 TEVA Company Information
  3. 4.1.2 TEVA Business Overview
  4. 4.1.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 TEVA Neurodegenerative Drugs Product Portfolio
  6. 4.1.5 TEVA Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Neurodegenerative Drugs Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis Neurodegenerative Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Luye Pharma
  20. 4.4.1 Luye Pharma Company Information
  21. 4.4.2 Luye Pharma Business Overview
  22. 4.4.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
  24. 4.4.5 Luye Pharma Recent Developments
  25. 4.5 Livzon Pharmaceutical
  26. 4.5.1 Livzon Pharmaceutical Company Information
  27. 4.5.2 Livzon Pharmaceutical Business Overview
  28. 4.5.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
  30. 4.5.5 Livzon Pharmaceutical Recent Developments
  31. 4.6 Kanghong Pharmaceutical
  32. 4.6.1 Kanghong Pharmaceutical Company Information
  33. 4.6.2 Kanghong Pharmaceutical Business Overview
  34. 4.6.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
  36. 4.6.5 Kanghong Pharmaceutical Recent Developments
  37. 4.7 Jingxin Pharmaceutical
  38. 4.7.1 Jingxin Pharmaceutical Company Information
  39. 4.7.2 Jingxin Pharmaceutical Business Overview
  40. 4.7.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
  42. 4.7.5 Jingxin Pharmaceutical Recent Developments
  43. 4.8 Pfizer
  44. 4.8.1 Pfizer Company Information
  45. 4.8.2 Pfizer Business Overview
  46. 4.8.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Pfizer Neurodegenerative Drugs Product Portfolio
  48. 4.8.5 Pfizer Recent Developments
  49. 4.9 Huahai Pharmaceutical
  50. 4.9.1 Huahai Pharmaceutical Company Information
  51. 4.9.2 Huahai Pharmaceutical Business Overview
  52. 4.9.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
  54. 4.9.5 Huahai Pharmaceutical Recent Developments
  55. 4.10 Hisun Pharmaceutical
  56. 4.10.1 Hisun Pharmaceutical Company Information
  57. 4.10.2 Hisun Pharmaceutical Business Overview
  58. 4.10.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
  60. 4.10.5 Hisun Pharmaceutical Recent Developments
  61. 4.11 Haisco Pharmaceutical
  62. 4.11.1 Haisco Pharmaceutical Company Information
  63. 4.11.2 Haisco Pharmaceutical Business Overview
  64. 4.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
  66. 4.11.5 Haisco Pharmaceutical Recent Developments
  67. 4.12 GlaxoSmithKline
  68. 4.12.1 GlaxoSmithKline Company Information
  69. 4.12.2 GlaxoSmithKline Business Overview
  70. 4.12.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
  72. 4.12.5 GlaxoSmithKline Recent Developments
  73. 4.13 Ark Pharmaceutical
  74. 4.13.1 Ark Pharmaceutical Company Information
  75. 4.13.2 Ark Pharmaceutical Business Overview
  76. 4.13.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
  78. 4.13.5 Ark Pharmaceutical Recent Developments
  79. 4.14 Dongcheng Biochemicals
  80. 4.14.1 Dongcheng Biochemicals Company Information
  81. 4.14.2 Dongcheng Biochemicals Business Overview
  82. 4.14.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
  84. 4.14.5 Dongcheng Biochemicals Recent Developments
  85. 4.15 BORA PHARMACEUTICALS
  86. 4.15.1 BORA PHARMACEUTICALS Company Information
  87. 4.15.2 BORA PHARMACEUTICALS Business Overview
  88. 4.15.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
  90. 4.15.5 BORA PHARMACEUTICALS Recent Developments
  91. 4.16 UCB
  92. 4.16.1 UCB Company Information
  93. 4.16.2 UCB Business Overview
  94. 4.16.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 UCB Neurodegenerative Drugs Product Portfolio
  96. 4.16.5 UCB Recent Developments
  97. 4.17 Merck Serono
  98. 4.17.1 Merck Serono Company Information
  99. 4.17.2 Merck Serono Business Overview
  100. 4.17.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Merck Serono Neurodegenerative Drugs Product Portfolio
  102. 4.17.5 Merck Serono Recent Developments
  103. 4.18 Boehringer Ingelheim
  104. 4.18.1 Boehringer Ingelheim Company Information
  105. 4.18.2 Boehringer Ingelheim Business Overview
  106. 4.18.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
  108. 4.18.5 Boehringer Ingelheim Recent Developments
  109. 4.19 Biogen Idec
  110. 4.19.1 Biogen Idec Company Information
  111. 4.19.2 Biogen Idec Business Overview
  112. 4.19.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
  114. 4.19.5 Biogen Idec Recent Developments
5 Global Neurodegenerative Drugs Market Scenario by Region
  1. 5.1 Global Neurodegenerative Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Neurodegenerative Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Neurodegenerative Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Neurodegenerative Drugs Sales by Region: 2027-2032
  5. 5.3 Global Neurodegenerative Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Neurodegenerative Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Neurodegenerative Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Neurodegenerative Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Neurodegenerative Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Neurodegenerative Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Neurodegenerative Drugs Market Facts & Figures by Country
  15. 5.5.1 Europe Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Neurodegenerative Drugs Sales by Country (2021-2032)
  17. 5.5.3 Europe Neurodegenerative Drugs Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.5.9 Nordic Countries
  24. 5.6 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Country
  25. 5.6.1 Asia Pacific Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032
  26. 5.6.2 Asia Pacific Neurodegenerative Drugs Sales by Country (2021-2032)
  27. 5.6.3 Asia Pacific Neurodegenerative Drugs Revenue by Country (2021-2032)
  28. 5.6.4 China
  29. 5.6.5 Japan
  30. 5.6.6 South Korea
  31. 5.6.7 India
  32. 5.6.8 Australia
  33. 5.6.9 China Taiwan
  34. 5.6.10 Southeast Asia
  35. 5.7 South America Neurodegenerative Drugs Market Facts & Figures by Country
  36. 5.7.1 South America Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032
  37. 5.7.2 South America Neurodegenerative Drugs Sales by Country (2021-2032)
  38. 5.7.3 South America Neurodegenerative Drugs Revenue by Country (2021-2032)
  39. 5.7.4 Mexico
  40. 5.7.5 Brazil
  41. 5.7.6 Argentina
  42. 5.7.7 Colombia
  43. 5.8 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
  44. 5.8.1 Middle East and Africa Neurodegenerative Drugs Market Size by Country: 2021 VS 2025 VS 2032
  45. 5.8.2 Middle East and Africa Neurodegenerative Drugs Sales by Country (2021-2032)
  46. 5.8.3 Middle East and Africa Neurodegenerative Drugs Revenue by Country (2021-2032)
  47. 5.8.4 Turkey
  48. 5.8.5 Saudi Arabia
  49. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Neurodegenerative Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Neurodegenerative Drugs Sales by Type (2021-2032) & (Tons)
  3. 6.1.2 Global Neurodegenerative Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Neurodegenerative Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Neurodegenerative Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Neurodegenerative Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Neurodegenerative Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Neurodegenerative Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Neurodegenerative Drugs Sales by Application (2021-2032) & (Tons)
  3. 7.1.2 Global Neurodegenerative Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Neurodegenerative Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Neurodegenerative Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Neurodegenerative Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Neurodegenerative Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Neurodegenerative Drugs Value Chain Analysis
  2. 8.1.1 Neurodegenerative Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Neurodegenerative Drugs Production Mode & Process
  5. 8.2 Neurodegenerative Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Neurodegenerative Drugs Distributors
  8. 8.2.3 Neurodegenerative Drugs Customers
9 Global Neurodegenerative Drugs Analyzing Market Dynamics
  1. 9.1 Neurodegenerative Drugs Industry Trends
  2. 9.2 Neurodegenerative Drugs Industry Drivers
  3. 9.3 Neurodegenerative Drugs Industry Opportunities and Challenges
  4. 9.4 Neurodegenerative Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst